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Abstract
To identify common variants influencing body mass index (BMI), we analyzed genome-wide
association data from 16,876 individuals of European descent. After previously reported variants
in FTO, the strongest association signal (rs17782313, P = 2.9 × 10−6) mapped 188 kb downstream
of MC4R (melanocortin-4 receptor), mutations of which are the leading cause of monogenic
severe childhood-onset obesity. We confirmed the BMI association in 60,352 adults (per-allele
effect = 0.05 Z-score units; P = 2.8 × 10−15) and 5,988 children aged 7–11 (0.13 Z-score units; P =
1.5 × 10−8). In case-control analyses (n = 10,583), the odds for severe childhood obesity reached
1.30 (P = 8.0 × 10−11). Furthermore, we observed overtransmission of the risk allele to obese
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offspring in 660 families (P (pedigree disequilibrium test average; PDT-avg) = 2.4 × 10−4). The
SNP location and patterns of phenotypic associations are consistent with effects mediated through
altered MC4R function. Our findings establish that common variants near MC4R influence fat
mass, weight and obesity risk at the population level and reinforce the need for large-scale data
integration to identify variants influencing continuous biomedical traits.
Although BMI is highly heritable, progress in identifying specific variants involved in
regulating weight has largely been confined to rare mutations causing severe, early-onset
monogenic forms of obesity1-6. Recently, the FTO gene was identified as the first locus
harboring common variants with an unequivocal impact on obesity predisposition and fat
mass at the population level7-9. To increase power to detect additional common variants
associated with these traits, and to improve our understanding of the molecular mechanisms
responsible, we carried out a large-scale meta-analysis of genome-wide association data
available for 16,876 individuals phenotyped for adult BMI.
Meta-analysis, under an additive model, of data from four European population-based
studies (n = 11,012) and three disease-case series (n = 5,864), all genotyped genotyped on
the Affymetrix GeneChip 500K array (Supplementary Table 1, Supplementary Fig. 1 and
Supplementary Note online), demonstrated that FTO variants had the strongest association
with BMI (for example, rs1121980: beta = 0.060 (95% CI = 0.039–0.082) Z-score units (that
is, log10-transformed BMI, standardized by gender and age, per-allele); P = 3.6 × 10−8)
(Supplementary Table 2, Supplementary Fig. 2 and Supplementary Note online). Among the
nine remaining signals with P < 10−5 (Supplementary Table 2 and Supplementary Figs. 2
and 3 online), we focused our initial attention on a cluster of associated SNPs on
chromosome 18q21 for which the most significant association resides at rs17782313 (P =
2.9 × 10−6).
This region seemed to contain at least two independent association signals (rs17782313 and
rs17700633: minor allele frequencies 24% and 30% respectively; Supplementary Table 3
online) with low pair-wise linkage disequilibrium (LD; r2 = 0.08, D′ = 0.33 in CEU
HapMap) mapping 109–188 kb from the coding sequence of MC4R (Fig. 1). MC4R
represents a compelling biological candidate, as rare coding mutations in the gene are the
leading cause of monogenic obesity in humans10.
Association analysis of imputed genotype data11, based on 16,876 samples from the seven
populations, for untyped HapMap SNPs across the region (55.7–56.4 Mb NCBI build 35)
showed that rs17782313 has the strongest association overall and that there were no other
(imputed or directly genotyped) SNPs with markedly stronger association than either
rs17782313 or rs17700633 (Fig. 1). Analyses of LD relationships, as well as haplotypic and
conditional analyses, established that these associations were not secondary to previously
reported associations with the V103I and I251L coding variants, of which the (rare) minor
alleles are weakly protective for obesity at the population level12-14 (Supplementary Note).
Several lines of evidence indicated that our association was unlikely to reflect latent
population substructure (Supplementary Note). Consequently, we focused follow-up efforts
on these two SNPs, seeking evidence for replication in 60,352 samples with measures of
adult BMI.
First, we genotyped both SNPs in ten adult population-based studies (combined n = 40,717)
and three disease-case series (n = 3,757) (Supplementary Fig. 1, Supplementary Table 1 and
Supplementary Note) of individuals all of European descent. Across all 44,474 individuals,
rs17782313 was strongly associated with BMI (combined per-allele effect = 0.049 (95% CI
= 0.033–0.065) Z-score units, P = 1.3 × 10−9; Supplementary Fig. 4a online), with less
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marked evidence for replication at rs17700633 (0.025 (0.011–0.040) Z-score units, P =
0.0007; Supplementary Fig. 4b).
Second, we obtained additional genotypes from six population-based studies (n = 13,240)
and two disease-case series (n = 2,638), all individuals of European origin undergoing
genome-wide association analysis within the Genetic Investigation of Anthropometric Traits
(GIANT) Consortium (Supplementary Table 1 and Supplementary Note). In these 15,878
individuals, rs17782313 was again associated with BMI (combined per-allele effect = 0.035
(0.006–0.063) Z-score units, P = 0.02; Supplementary Fig. 4c), with comparable effect size
and evidence for replication at rs17700633 (0.041 (0.015–0.067) Z-score units, P = 0.002;
Supplementary Fig. 4d).
Combining data across all 77,228 genotyped adults, we found that each copy of the
rs17782313 C allele was associated with a difference in BMI of 0.049 (0.037–0.061) Z-
score units (P = 2.8 × 10−15; Fig. 2 and Table 1), equivalent to ~0.22 kg m−2. Evidence for
association at rs17700633 was weaker (0.033 (0.022–0.045) Z-score units or ~0.15 kg m−2;
P = 4.6 × 10−9) (Supplementary Fig. 4e and Supplementary Table 4 online). Although initial
assessment based on LD patterns from the HapMap had suggested that the effect at
rs17700633 was independent of that at rs17782313, conditional analysis conducted on our
data show that the effect of the former is substantially attenuated and no longer reaches a
strong degree of statistical significance (P = 0.002 for rs17700633 after conditioning on
rs17782313; Supplementary Fig. 4f,g and Supplementary Note). We did not find any
evidence for a significant difference in effect size (P = 0.11) between men (0.058 (0.041–
0.076) Z-score units) and women (0.039 (0.022–0.055)) at rs17782313 (Supplementary Fig.
4h,i).
The C allele at rs17782313 was positively associated with adult height (per-allele effect =
0.030 (0.018–0.042) Z-score units; P = 8.7 × 10−7; equivalent to ~0.21 cm) (Supplementary
Fig. 4j). Consequently, the association with weight was even stronger than that with BMI
(per-allele effect for rs17782313[C] = 0.059 (0.047–0.071) Z-score units, P = 2.8 × 10−21;
equivalent to ~760 g), indicating that rs17782313 influences overall adult size
(Supplementary Fig. 4k). Across the 77,228 adult samples, rs17782313 was associated with
an ~8% per-allele increase in the odds of being overweight (BMI ≥ 25 kg m−2; ORoverweight
= 1.08 (1.05–1.11), P = 1.6 × 10−9) and ~12% of being obese (BMI ≥ 30 kg m−2; ORobesity =
1.12 (1.08–1.16), P = 5.2 × 10−9) (Supplementary Fig. 4l,m). In a separate obesity case-
control study of 2,766 French adults (Supplementary Table 1), there was a 31% per-allele
increase in the odds of being morbidly obese (BMI ≥ 40 kg m−2; ORmorbid-obesity = 1.31
(1.15–1.49), P = 5.6 × 10−5).
To understand the effect of rs17782313 on regulation of weight in early life, we first
examined 5,988 children from the Avon Longitudinal Study of Parents and Children
(Supplementary Table 1). There was no association with birth weight or weight up to 42
months (Supplementary Table 5 online). However, in children aged 7–11 y, each additional
copy of rs17782313[C] was associated with a BMI difference of between 0.10 and 0.13 Z-
score units (P < 7.3 × 10−6) (Fig. 3 and Supplementary Table 5), twice that observed in
adults (P = 0.001). In these children, the association with BMI was mediated exclusively
through an effect on weight, with no detectable effect on height (Supplementary Table 5).
Body composition data for 5,281 9-year-old children showed that genotype-associated
differences in weight and BMI reflected disproportionate effects on fat mass (per-allele
effect of rs17782313[C] on percentage body fat = 0.10 (0.05–0.14) Z-score units, P = 3.0 ×
10−5; Fig. 3 and Supplementary Table 5).
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These findings were confirmed in three case-control studies of children and adolescents with
severe early-onset obesity (Supplementary Note, Supplementary Fig. 1 and Supplementary
Table 1). In each, rs17782313 was associated with a significant increase in the risk of
extreme obesity: the combined estimate of the OR was 1.30 (1.20–1.41; P = 8.0 × 10−11;
Fig. 3 and Supplementary Table 1). In 660 nuclear families, ascertained through children or
adolescents with extreme obesity (BMI > 95th percentile), there was a significant
overtransmission of the C allele to the obese offspring (56% transmission rate, PDT-avg =
2.42 × 10−4), providing further evidence that the association does not reflect population
stratification (Supplementary Note, Supplementary Fig. 1 and Supplementary Table 1).
Common variants near MC4R and FTO seem to have additive effects on BMI (Fig. 4).
When comparing individuals with no risk alleles at either locus (19% of the population) with
those homozygous at both (1%), the point estimate of the BMI difference amounts to 0.26 Z-
score units (or ~1.17 kg m−2) in adults and 0.56 Z-score units in children.
Having observed convincing BMI and obesity associations in both adults and children, we
next sought refinement of the association signal through meta-analyses of genotyped and
imputed data and analysis of LD patterns (Supplementary Fig. 5a online) across 1 Mb of
flanking sequence (including the coding region of MC4R itself). In contrast to the original
analysis of all seven studies (Fig. 1), the meta-analysis restricted to the four population-
based studies (Supplementary Fig. 5b) identified three SNPs (rs12955983, rs718475,
rs9956279) that had association signals of comparable or stronger magnitude to rs17700633
and rs17782313. When we extended this meta-analysis to include data on all 32,301
individuals with available regional data (Supplementary Fig. 5c), only rs718475 and
rs9956279 showed more significant association results compared to rs17700633 and
rs17782313. However, direct genotyping of these SNPs, as well as conditional analysis,
showed that these estimates of association were inflated and indicated that rs17782313
remains the most significantly associated variant for which imputed or typed data are
currently available (Supplementary Note). Our findings cannot be explained by previously
reported associations at rare variants such as V103I and I251L, which have only modest
allelic association with rs17782313 (r2 = 0.001; D′ = 0.48 and r2 = 0.001; D′ = 0.49,
respectively; Supplementary Note). Comprehensive resequencing and fine mapping will be
required to unambiguously identify the causal variants, although these probably lie within a
190-kb recombination interval between the coding sequences of PMAIP1 and MC4R
(Supplementary Fig. 5a). PMAIP1, encoding the protein Noxa, is a putative HIF1A
(hypoxia-inducible factor, alpha)-regulated proapoptotic gene15 and a relatively unlikely
candidate for a role in weight regulation. In contrast, humans with rare functional mutations
in MC4R sequence are known to develop severe early-onset obesity16, and analogous
phenotypes are seen in murine models of Mc4r disruption17. This strong biological
candidacy points to disruption of the transcriptional control of MC4R as the likely functional
mechanism, even though the associated variants lie 109–188 kb downstream of the MC4R
coding sequence. Low or absent MC4R expression in available expression QTL datasets
(derived from lymphocytes18-20 and cerebral cortex21) precluded efforts to obtain evidence
for cis-transcriptional phenotypes associated with rs17782313 or other nearby SNPs. There
was no evidence for cis effects between any of the SNPs within this interval and expression
of PMAIP1 in lymphocytes (refs. 18-20 and E.T.D., unpublished data) or cerebral cortex21.
In the absence of direct functional evidence relating these variants to MC4R expression, we
asked whether they recapitulated phenotypic patterns characteristic of rare, severe coding
mutations in MC4R. These include early-onset obesity, increases in lean mass and bone
mineral density and enhanced linear growth16. The rs17782313-related associations with
adult height clearly indicate an impact on linear growth and are consistent with the
phenotype seen in rare, severe coding mutations in MC4R. Furthermore, the
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disproportionate BMI effect size in children (as compared to adults) is also consistent with
the early-onset obesity characteristic of rare MC4R mutations. Neither such effect was
observed for variants at FTO8. Children carrying the C allele at rs17782313 had modest
increases in lean and bone mass, although these were similar to those observed for variants
at FTO (Fig. 3, Supplementary Note and Supplementary Table 6 online).
These findings have implications for ongoing efforts to identify variants influencing
common continuous traits such as weight and BMI. First, as with variants in FTO, common
variants near MC4R make only a modest contribution to overall variance (~0.14% for adult
BMI, and ~0.26% for fat mass at age 9). Of the other eight signals emerging from our meta-
analysis of 16,876 individuals, there was clear evidence of replication of the SNP within
FTO in additional (n > 34,000) samples, whereas SNPs rs10498767 (chromosome 6;
replication P = 0.009; meta-analysis P = 2.3 × 10−5) and rs748192 (chromosome 3;
replication P = 0.05; meta-analysis P = 2.9 × 10−5) showed some nominal evidence of
replication; these signals, in particular, will benefit from further replication studies to
establish their contribution to obesity-related phenotypes (Supplementary Table 7 online).
Second, our finding provides a powerful example of overlap in the genetic determinants of
monogenic and multifactorial forms of the same condition. Third, as with recent findings in
diseases such as prostate cancer22 and type 2 diabetes23-26, our study suggests that variants
mapping tens or hundreds of kilobases from adjacent coding sequence can have convincing
phenotypic effects, presumably via remote effects on expression or translation. Finally,
primary identification of these signals involved analysis of genome-wide association data
from over 16,000 individuals, with further confirmation and initial characterization of the
locus using over 90,000 samples. Although more substantial influences on weight and BMI
may have been overlooked as a result of the incomplete coverage offered by contemporary
genotyping arrays, especially for structural and low frequency variants, this study illustrates
the scale of the endeavor that will be required for detection of additional variants influencing
traits such as these.
METHODS
Genome-wide association samples
Five of the seven genome-wide scan studies were part of the Wellcome Trust Case Control
Consortium (WTCCC) and have been described previously26: the type 2 diabetes (WTCCC-
T2D, n = 1,924), hypertension (WTCCC-HT, n = 1,952) and coronary artery disease
(WTCCC-CAD, n = 1,988) case samples, and the UK Blood Service (WTCCC-UKBS, n =
1,485) and British 1958 Birth Cohort (WTCCC-BC58, n = 1,479) controls. The EPIC
Obesity study comprises a representative sample (n = 2,566) nested within the EPIC-Norfolk
Study27, a population-based cohort study of 25,663 men and women of European descent
aged 39–79 y recruited in Norfolk, UK between 1993 and 1997. Of these, 2,415 were
included in the analyses. The CoLaus study28 is a cross-sectional study of a random sample
of 6,188 extensively phenotyped European men and women, aged 35–75 y, living in
Lausanne, Switzerland, of whom 5,633 were included in the analyses. Height and weight
were measured using standard anthropometric techniques in all studies, except for WTCCC-
CAD and WTCCC-UKBS, for which height and weight were self reported. Basic
descriptive characteristics for all genome-wide association studies are presented in
Supplementary Table 1. All participants gave written informed consent, and project
protocols were approved by the appropriate research ethics committees (Supplementary
Note).
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Genome-wide SNP genotyping and quality control
All seven genome-wide association (GWA) studies were genotyped using Affymetrix
GeneChip 500K array set. Genotypes were called using the CHIAMO genotype calling
software26 for all studies, apart from the EPIC-Obesity and CoLauS studies, for which the
BRLMM algorithm was used. Here, we report 359,062 SNPs that passed quality control in
all four population-based studies (EPIC-Obesity, British 1958 Birth Cohort, CoLaus and UK
Blood Services) and 344,883 SNPs that passed quality control in all seven (four population-
based plus three case-series studies, WTCCC-HT, WTCCC-T2D and WTCCC-CAD). Each
study had applied genotyping quality control criteria and done tests for population
stratification: correction for population substructure was done by principal components in
the CoLaus cohort (Supplementary Note). Each study had excluded individuals with
evidence of non-European ancestry on the basis of genome-wide association data (for
example, through multidimensional scaling)26. The genomic inflation factor (λ) of each
GWA study ranged from 1.009 to 1.024, indicating that the extent of residual population
substructure is modest (Supplementary Fig. 3). In addition, none of the markers recently
shown to be informative for geographical origin in the UK26 associated with BMI (all P >
0.01). Additional details are available in Supplementary Note.
Replication genotyping
Initial replication of rs17782313 and rs17700633 was done in 13 collections (n = 44,474) for
which DNA was available for genotyping (Supplementary Table 1 and Supplementary
Note). We also sought replication in 18,878 individuals from eight additional samples for
which rs17782313 and rs17700633 genotypes were available as part of ongoing GWA
studies (Supplementary Table 1 and Supplementary Note). Further, we genotyped
rs17782313 in samples from a French adult obesity case-control study (n = 2,766), from the
Essen Obesity Family study (n = 2,280) and in three samples informative for childhood or
adolescent BMI (n = 9,654). Genotypes for a fourth study of childhood BMI (Essen Obesity
Study, n = 929) were available from their genome-wide association data. In total, 59,174
individuals were directly genotyped, and 16,807 individuals provided genotypes from their
respective GWA scans (Supplementary Table 1 and Supplementary Note). Of the former,
37,819 samples were genotyped using TaqMan SNP genotyping assay (Applied Biosystems)
according to the manufacturer's protocol, and 21,355 were genotyped by KBiosciences using
a fluorescence-based competitive allele-specific PCR (KASPar). Duplicates were assayed
with >99% concordance rates. Of the nine samples providing genotypes from genome-wide
association data, five (SardiNIA, KORA, DGI T2D cases, DGI controls and Essen Obesity
Study) were genotyped on the Affymetrix GeneChip 500K, and four were genotyped on the
HumanHap300 (FUSION T2D cases, FUSION controls and PLCO), HumanHap240 (also
PLCO) or HumanHap550 (NHS) Illumina arrays. As rs17782313 and rs17700633 were not
present on the Illumina platforms, unobserved genotypes were imputed with high accuracy
(predicted r2 ≥ 0.89) using MACH. Of the SardiNIA population, 1,412 individuals were
genotyped for the Affymetrix GeneChip 500K; the remaining individuals were genotyped
with the Affymetrix Mapping 100K array, and these marker data were used to impute
genotypes at SNPs in the ‘500K’ set for the remaining 2,893 individuals not typed with this
technology9,29. Residual relatedness in the SardiNIA and FUSION samples was dealt with
statistically (see below). Overall call rates across studies averaged 98.1%, and there were no
departures from Hardy-Weinberg equilibrium (P > 0.01 in each study) (Supplementary
Table 3 and Supplementary Note). Informed consent and ethical approval was obtained for
all studies. Additional details are available in Supplementary Note.
Genome-wide association analyses and meta-analyses
BMI was log10-transformed and standardized to Z scores before analyses. EPIC-Obesity,
British BC58 and CoLaus calculated sex- and age-specific Z scores, and WTCCC-UKBS,
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WTCCC-T2D, WTCCC-HT and WTCCC-CAD used sex-specific Z scores, adjusting for
age in the analyses. Each GWA study performed linear regression (additive model) to test
for association between each SNP and BMI Z score using PLINK (WTCCC-T2D, WTCCC-
UKBS, WTCCC-CAD, CoLauS), SAS/Genetics 9.1 (EPIC-Obesity Study), STATA 8.1
(British 1958 BC) or R (WTCCC-HT). Subsequently, summary statistics of the SNP-BMI
associations of each GWA study were combined in meta-analyses using the inverse
variance–weighted method with a fixed-effects model30. Meta-analyses were done by
combining the four population-based studies (EPIC-Obesity, British 1958 BC, CoLaus and
WTCCC/UKBS) as well as all seven GWA studies. Variants that showed marked evidence
of heterogeneity (P < 0.10) across the studies were not considered for replication. Meta-
analyses were done with SAS 9.1. The overall results of the meta-analysis were visualized
using PLINK (Supplementary Fig. 2), and the top hits from our scan and the replication data
are presented in Supplementary Table 2. Additional details are available Supplementary
Note.
Replication in adult population-based studies and case series and meta-analyses
Replication analyses were also based on sex-specific log10BMI Z scores, using linear
regression (additive model) while adjusting for age (and other appropriate covariates such as
‘center’). Analyses were also done with BMI log10-transformed (but not standardized) for
presentation of geometric means and 95% CIs (Table 1 and Supplementary Table 4). For
relevant analyses, height was standardized to sex-specific Z scores, whereas weight was
log10-transformed before standardizing. Again, association was tested using linear
regression assuming an additive model, adjusted for age and other appropriate covariates.
Case-control analyses (for obesity and over-weight) within population-based samples were
done by comparing overweight (BMI ≥ 25 kg m−2) and obese (BMI ≥ 30 kg m−2) to normal-
weight (BMI < 25 kg m−2) individuals. Logistic regression was used to test for association
between genotype and overweight/obesity, adjusted for age and sex. Similar methods were
used to test for association with case status in the French adult obesity case-control study.
All analyses were also done for men and women separately. In samples featuring
appreciable numbers of individuals with significant degrees of relatedness (SardiNIA,
FUSION), residual kinship was accounted for using a score test as previously described29.
Analyses were done in Stata/s.e.m. 9.2 for Windows, PLINK, SPSS 14.1 software and SAS/
Genetics 9.1. The summary statistics (beta (or OR) and s.e.m. (or 95% CI)) for each of the
separate studies were combined in meta-analyses using the inverse variance–weighted
method assuming a fixed-effects model, conducted in SAS 9.1. To provide approximate
effect-size estimates expressed in BMI units (kg m−2), we translated from the Z-score unit
differences using the s.d. of raw BMI (a mean s.d. of 4.5 kg m−2 in the population-based
cohorts). This method was also applied to provide approximate effect size estimates for
reporting height (mean s.d. of 7 cm) and weight (mean s.d. of 13.4 kg) data. Conditional
analyses were done to investigate the dependencies between the BMI effects at rs17782313
and rs17700633: we tested for association between rs17700633 and BMI (sex-specific
log10-transformed), while adjusting for age and rs17782313 (and vice versa). Summary
statistics were, as before, meta-analyzed using the inverse variance–weighted method with
Stata 9.2.
Analyses in childhood studies
The population-based ALSPAC study was used to test for association between rs17782313
and measures of anthropometry and body composition. Weight and height during the first 42
months of life were expressed as SDS relative to British 1990 scales. Birth weight was
standardized by sex and gestational age. BMI and weight between age 7 and 11, as well as
body fat percentage, DXA fat mass, DXA lean mass and DXA bone mass at age 9 were
log10-transformed, whereas height remained untransformed before calculation of sex-
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specific Z scores. Linear regression (additive model) was used to test for association
between rs17782313 genotypes and these anthropometric measures. Analyses were done in
Stata/s.e.m. 9.2 for Windows. In the three childhood or adolescent case-control series, we
used logistic regression to test for association with severe obesity. Although the three studies
used slightly different definitions of severe obesity (3 s.d. above population mean and age of
onset < 10 y in SCOOP-UK, BMI > 95th percentile in the Essen Obesity study, and BMI ≥
97th percentile in the French Childhood Obesity study), there was no detectable
heterogeneity between the estimates derived, and the summary statistics (ORs and 95% CIs)
of each study were combined in meta-analyses as described above. In a separate set of 660
nuclear families of the Essen Obesity Family study, we used a pedigree transmission
disequilibrium test (PDT average) to test for overtransmission of the rs17782313 C allele to
the obese offspring. In addition, we determined genotype relative risks (GRR), which are
robust against deviations from Hardy-Weinberg equilibrium.
Additional consortium authors are as follows:
The Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial: Kevin B
Jacobs, Stephen J Chanock & Richard B Hayes
KORA: Claudia Lamina, Christian Gieger, Thomas Illig, Thomas Meitinger & H-Erich
Wichmann
Nurses' Health Study: Peter Kraft, Susan E Hankinson, David J Hunter & Frank B Hu
Diabetes Genetics Initiative: Helen N Lyon, Benjamin F Voight, Martin Ridderstrale &
Leif Groop
The SardiNIA Study: Paul Scheet, Serena Sanna, Goncalo R Abecasis, Giuseppe Albai,
Ramaiah Nagaraja & David Schlessinger
FUSION: Anne U Jackson, Jaakko Tuomilehto, Francis S Collins, Michael Boehnke &
Karen L Mohlke
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Regional plot of chromosome 18q21 (55,700–56,400 kb), showing the association signals
for obesity for the meta-analysis of all 16,876 samples with genome-wide association scans.
On the x axis is chromosomal position in kilobases (as NCBI build 35 coordinates), and on
the y axis is the P value for association (expressed as −log10 P value). The imputed data
signals are shown in gray diamonds and the directly genotyped signals in white. Estimated
recombination rates (taken from HapMap) are plotted (light blue) to reflect the local LD
structure around the associated SNP. Gene annotations were taken from the University of
California Santa Cruz genome browser. The yellow diamond corresponds to the directly
genotyped SNP in this region, which shows the strongest association with obesity
(rs17782313, P = 2.9 × 10−6), the lower blue diamond represents the result from rs17700633
(P = 4.8 × 10−5, directly genotyped), and the green diamond represents the result from
rs2229616 (or V103I, P = 0.056, imputed). LD structure across the interval, as calculated by
D′, and r2 measures are shown in Supplementary Figure 5a.
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Figure 2.
Meta-analysis plot showing the rs17782313[C] per-allele effect size on BMI in 77,228
adults, expressed in log10BMI sex-specific Z-score units.
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Figure 3.
Effects of rs17782313 on regulation of weight in early life. (a) Longitudinal data for BMI at
age 7–11 for children in the ALSPAC study by rs17782313 genotypes. Mean values
represented as geometric means and back-transformed 95% confidence intervals. P values
represent significance of the additive model (per-allele effect) of log10-transformed data,
adjusted for sex. (b) Association between rs17782313 and body fat percentage in 9-year-old
children from the ALSPAC study. Mean values represented as geometric means and back-
transformed 95% confidence intervals. P values represent significance of the additive model
(per-allele effect) of log10-transformed data, adjusted for sex. (c) Meta-analysis plot
showing the rs17782313[C] per-allele effect size on risk of severe obesity in childhood and
adolescence in 10,583 children from three studies.
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Figure 4.
Association between the combined rs17782313 and FTO genotypes and BMI in adults
(EPIC-Norfolk, n = 15,622) and children (ALSPAC age 7 years, n = 5,779). BMI is
expressed in log10BMI Z-score units adjusted for age (in adults) and sex. Both SNPs have a
significant additive effect on BMI in adults (rs17782313, P = 4.0 × 10−4; rs1121980, P = 2.0
× 10−14) and in children (rs17782313, P = 8.0 × 10−6; rs9939609, P = 7.6 × 10−5).
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